Imel Biotherapeutics

About:

Imel Biotherapeutics develops cell-based therapies to treat patients with mitochondrial disorders.

Description:

Imel Biotherapeutics develops cell-based therapies to treat patients with mitochondrial disorders. It uses a proprietary mitochondrial replaced cells technology, helping physicians to treat multiple patients with mitochondrial genetic or age-related disorders. The company was founded in 2019 and is based in Waltham, Massachusetts.

Total Funding Amount:

$15M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Waltham, Massachusetts, United States

Founded Date:

2019-01-01

Founders:

Silvia Noiman

Number of Employees:

11-50

Last Funding Date:

2021-11-15

IPO Status:

Private

Industries: